`
`THIS FOURTH LUCENTJS DEVELOPMENT AGREEMENT AMENDMENT ("Amendment'') is
`entered into, effective as of the Amendment Effective Date, by and between Novartis Phanna AG, a
`company duly organized and existing under Swiss law and
`Lichtstrasse 35, 4056 Basel, Switzerland ("Novartis"), an
`duly organized and existing under German law and located
`), wit-
`Germany _
`acting on behalf of itself and its Affiliates
`
`at
`pany
`
`I d in, and such acting subject to, the Agreement), including
`
`com anv dul or ani:zed and existin under German law a d
`d a
`re erre to eac 1 m 1v1 ua y as a "Party- an toge er as the "Parties ,
`
`·t i s
`
`· cipal place of business
`, and with Novartis and
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` purposes;
`
`Page I of 14
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION , SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(CH)00170896
`
`Novartis Exhibit 2133.001
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`